Field trial of rhesus rotavirus or human-rhesus rotavirus reassortant vaccine of VP7 serotype 3 or 1 specificity in infants. The Elmwood, Panorama, and Westfall Pediatric Groups.
Field trial of rhesus rotavirus or human-rhesus rotavirus reassortant vaccine of VP7 serotype 3 or 1 specificity in infants. The Elmwood, Panorama, and Westfall Pediatric Groups.
复制标题
婴儿中 VP7 血清型 3 或 1 特异性的恒河猴轮状病毒或人-恒河猴轮状病毒重配疫苗的现场试验。
DOI：
10.1093/infdis/166.2.235
复制
发表时间：
1992
期刊：
影响因子：
--
通讯作者：
Dolin,R
中科院分区：
文献类型：
--
作者：
Madore,HP;Christy,C;Pichichero,M;Long,C;Pincus,P;Vosefsky,D;Kapikian,AZ;Dolin,R
在223名2-4月龄婴儿的安慰剂对照田间试验中，对口服恒河猴轮状病毒活疫苗（RRV，VP 7血清3型）和人源恒河猴重组轮状病毒疫苗（DxRRV，VP 7血清1型）进行了评价。两种疫苗均为轻度反应原性，但在接种后10天内耐受性良好。RRV和DxRRV具有免疫原性，分别在78%和71%的疫苗接种者中诱导血清抗体应答。在接种后的第一个季节，RRV疫苗和DxRRV疫苗对轮状病毒相关疾病的有效性分别为66%（P= .01）和77%（P= .002）。在三个轮状病毒季节中，RRV疫苗对轮状病毒相关疾病的有效性为51.2%（P= .045），DxRRV疫苗为67.3%（P= .006）。RRV疫苗提供了58.5%（P= 0.041）的异型保护，DxRRV疫苗提供了72.8%（P= 0.005）的同型保护，在三个赛季对主要血清型1轮状病毒。
Orally administered live rhesus monkey rotavirus vaccine (RRV, VP7 serotype 3) and humanrhesus reassortant rotavirus vaccine (DxRRV, VP7 serotype 1) were evaluated in a placebo-controlled field trial of 223 infants 2–4 months old. Both vaccines were mildly reactogenic but were generally well tolerated in the 10 days after vaccination. RRV and DxRRV were immunogenic, inducing serum antibody responses in 78% and 71% of the vaccinees, respectively. Efficacy of RRV vaccine was 66% (P= .01) and of DxRRV vaccine 77% (P= .002) against rotavirus-associated illness in the first season after vaccination. Efficacy of RRV vaccine against rotavirus-associated illness over three rotavirus seasons was 51.2% (P= .045) and of DxRRV vaccine was 67.3% (P= .006). RRV vaccine provided heterotypic protection of 58.5% (P= .041) and DxRRV vaccine provided homotypic protection of 72.8% (P= .005) over three seasons against the predominant serotype 1 rotavirus.